This site is intended for healthcare professionals

Use of the AstraZeneca COVID-19 (AZD1222) vaccine: updated Joint Committee on Vaccination and Immunisation (UK) statement.

Read time: 1 mins
Last updated:28th Jun 2021
Published:9th May 2021
Department of Health & SOcial Care (UK) Statement made on 7 May 2021:There have been reports of extremely rare adverse events of concurrent thrombosis (blood clots) and thrombocytopenia (low platelet count) following vaccination with the first dose of AstraZeneca ChAdOx1 nCoV-19 vaccine (AZD1222).
Condition: Coronavirus/COVID-19 Infection
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest